LEVEL OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN MEDULLARY AND PAPILLARY THYROID CARCINOMAS

Natalia Kobrynska; Volodymyr Pushkarev; Natalia Levchuk; Bogdan Guda; Ihor Komisarenko; Olga Furmanova; Olena Kovzun

doi:10.21856/j-PEP.2026.2.01

Authors

Kobrynska N. Ya. SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0001-8698-9793
Pushkarev V. M. SI “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0003-0347-7771
Levchuk N. I. SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0003-0482-5176
Guda B. B. SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0002-9181-0679
Komisarenko I. I. SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0002-1808-667X
Furmanova O. V. SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0002-9414-7761
Kovzun O. I. SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0002-6906-6636

DOI:

https://doi.org/10.21856/j-PEP.2026.2.01

Keywords:

monocyte chemoattractant protein-1, medullary thyroid carcinoma, papillary thyroid carcinoma, metastasis, biomarker

Abstract

Monocyte chemoattractant protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), is a prototypical member of the C-C chemokine superfamily (MCP-1/2/3/4) that signals through G protein–coupled receptors to orchestrate leukocyte recruitment. By regulating the trafficking and activation of monocytes and basophils, MCP-1 critically modulates inflammatory responses. In the oncologic context, MCP-1 promotes tumor progression and metastatic dissemination through the recruitment of tumor-associated macrophages, thereby fostering a microenvironment conducive to cancer cell survival, migration, and invasion. This study aimed to comparatively evaluate MCP-1 levels in conditionally normal (CN) thyroid tissue, primary medullary thyroid carcinoma (MTC) tissues, and corresponding metastatic (Mts) lesions, as well as in blood plasma from patients with medullary thyroid carcinoma and papillary thyroid carcinoma (PTC) with and without metastases.

Materials and methods. Postoperative thyroid tissue specimens and peripheral blood plasma were collected from patients undergoing surgical treatment. MCP-1 concentrations were quantified using enzyme-linked immunosorbent assay (ELISA).

Results. MCP-1 expression was significantly elevated in primary MTC tissues without metastases compared with matched CN thyroid tissue. In metastatic MTC, tissue MCP-1 levels were increased more than threefold relative to corresponding normal tissue, with the highest expression observed in lymph node metastatic deposits. Consistently, circulating MCP-1 concentrations were significantly higher in patients with metastatic MTC than in those with non-metastatic disease. No significant difference in plasma MCP-1 concentration was found between metastatic РTC and РTC without metastases.

Conclusions. MCP-1 expression is markedly upregulated in metastatic versus non-metastatic medullary thyroid carcinoma at both tissue and systemic levels. These findings implicate MCP-1 as a potential preoperative biomarker for stratifying metastatic risk in medullary thyroid carcinoma.

References

1. Komisarenko II, Guda BB, Kroups’ka IV, et al. Endokrynologia 2025;30(1): 51-59. http://doi.org/10.31793/1680-1466.2025.30-1.51.

2. Guda BB, Pushkarеv VM, Kovalenko AE, et al. Endokrynologia 2019;24(1): 53-65. http://doi.org/10.31793/1680-1466.2019.24-1.53.

3. Li Z, Wang N, Li X, et al. Oncol Lett 2025;30(5): 520. http://doi.org/10.3892/ol.2025.15266.

4. Deshmane SL, Kremlev S, Amini S, Sawaya BE. J Interferon Cytokine Res 2009;29(6): 313-326. http://doi.org/10.1089/jir.2008.0027.

5. Wang L, Lan J, Tang J, Luo N. Oncol Lett 2022;23(1): 26. http://doi.org/10.3892/ol.2021.13144.

6. Kanevskyi VA, Pushkarev VM. Cytol Genet 2017;51(6): 462-469. http://doi.org/10.3103/S0095452717060044.

7. Singh S, Anshita D, Ravichandiran V. Int Immunopharmacol 2021;101(Pt B): 107598. http://doi.org/10.1016/j.intimp.2021.107598.

8. Fujisaki K, Fujimoto H, Sangai T, et al. Breast Cancer Res Treat 2015;150(2): 255-263. http://doi.org/10.1007/s10549-015-3318-2.

9. Wu Q, Li B, Li Z, et al. J Hematol Oncol 2019;12(1): 95, available at: https://link.springer.com/article/10.1186/s13045-019-0778-6.

10. Yoshimura T, Li C, Wang Y, Matsukawa A. Cell Mol Immunol 2023;20(7): 714-738. http://doi.org/10.1038/s41423-023-01013-0.

11. Bradford ММ. Anal. Biochem 1976;72(1): 248-254. http://doi.org/10.1016/0003-2697(76)90527-3.

12. Pernot S, Evrard S, Khatib AM. Front Immunol 2022;13: 850856. http://doi.org/10.3389/fimmu.2022.850856.

13. Garifulin OM, Filonenko VV, Bdzhola AV, et al. Cytol Genet 2023;57(4): 305-311. http://doi.org/10.3103/S0095452723040059.

14. Sun C, Li X, Guo E, et al. Oncogene 2020;39(8): 1681-1695. http://doi.org/10.1038/s41388-019-1090-1.

15. Yoshimura T. Cytokine 2017;98: 71-78. http://doi.org/10.1016/j.cyto.2017.02.001.

16. Tanaka K, Kurebayashi J, Sohda M, et al. Thyroid 2009;19(1): 21-25. http://doi.org/10.1089/thy.2008.0237.

17. Qin Y, Ding W, Wu X, Qin D. J Biochem Mol Toxicol 2024;38(12): e70060. http://doi.org/10.1002/jbt.70060.

18. Kimura T, Kruhlak M, Zhao L, et al. Am J Cancer Res 2024;14(12): 5812-5825, available at: https://e-century.us/files/ajcr/14/12/ajcr0161725.pdf.

19. Candelotti E, De Luca R, Megna R, et al. Front Cell Dev Biol 2021;9: 651492. http://doi.org/10.3389/fcell.2021.651492.

20. Dutta P, Sarkissyan M, Paico K, et al. Breast Cancer Res Treat 2018;170(3): 477-486. http://doi.org/10.1007/s10549-018-4760-8.

21. Mohamed HT, El-Ghonaimy EA, El-Shinawi M, et al. Toxicol Appl Pharmacol 2020;401: 115092. http://doi.org/10.1016/j.taap.2020.115092.

22. Lindholm PF, Sivapurapu N, Jovanovic B, Kajdacsy-Balla A. J Clin Cell Immunol 2015;6(2): 308. http://doi.org/10.4172/2155-9899.1000308.

23. Liu JF, Chen PC, Chang TM, Hou CH. J Exp Clin Cancer Res 2020;39(1): 254. http://doi.org/10.1186/s13046-020-01756-y.

24. Kobrynska NYa, Pushkarev VM, Levchuk NI, et al. Probl Endocrine Pathol 2025;4: 14-18. http://doi.org/10.21856/j-PEP.2025.4.02.

25. Kobrynska N, Pushkarev V, Levchuk N, et al. Endokrynologia 2025;30(2): 119-123. http://doi.org/10.31793/1680-1466.2025.30-2.119.

26. Kobrynska NYa, Pushkarev VM, Levchuk NI, et al. Endokrynologia 2025;30(4): 305-316. http://doi.org/10.31793/1680-1466.2025.30-3.305.

27. Zinych PP, Pushkarev VM, Levchuk NI, et al. Endokrynologia 2025;30(4): 291-295. http://doi.org/10.31793/1680-1466.2025.30-4.291.

28. Zinych PP, Pushkarev VM, Levchuk NI, et al. Mìžnar Endokrinol Žurn 2026;22(1): 11-14. http://doi.org/10.22141/2224-0721.22.1.2026.1668.

LEVEL OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN MEDULLARY AND PAPILLARY THYROID CARCINOMAS

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License

Most read articles by the same author(s)

Similar Articles

facebook

issn

Make a Submission

flags

indexing

Language